Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Atezolizumab monotherapy
d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
e. Bevacizumab
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Dabrafenib with Trametinib
k. Docetaxel monotherapy
l. Durvalumab
m. Erlotinib
n. Gefitinib
o. Gemcitabine
p. Nintedanib with Docetaxel
q. Nivolumab
r. Osimertinib
s. Paclitaxel
t. Pembrolizumab monotherapy
u. Pembrolizumab chemo in combination
v. Pemetrexed with Carboplatin
w. Pemetrexed with Cisplatin
x. Vinorelbine and cisplatin/carboplatin
y. Any other active systemic anti-cancer therapy (SACT)
z. Palliative care only
Q2. Could you please provide the total number of patients treated with any systemic anti-cancer therapy (SACT) in the last three months for:
a. Total non-small cell lung cancer (NSCLC)
b. Squamous non-small cell lung cancer (Sq NSCLC)
c. Non-squamous non-small cell lung cancer (Non-Sq NSCLC)
Q3. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?
